drugset / Trial / NCT05316480
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
NaSingle-groupOpen-labelTreatment
Summary
The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2025-04-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |